Currently, around 50 companies claim to manufacture peptide-based therapeutics; such players also claim to be capable of providing a variety of additional services to their clients
The inherentadvantages of peptide therapeutics, such as small size, low immunogenicity andbetter cellular uptake, has led to a rise in interest in such interventions.
129
views

The inherentadvantages of peptide therapeutics, such as small size, low immunogenicity andbetter cellular uptake, has led to a rise in interest in such interventions.This is anticipated to create significant opportunities for CMOs offeringpeptide manufacturing services. However, in order to meet the current andfuture demand, contract manufacturers may need to strengthen their respectivecapabilities and expand available capacities.

 

To order this 250+ pagereport, which features 100+ figures and 110+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/peptide-therapeutics-manufacturing/305.html

 

The USD 3.2 billion (by 2030) financial opportunitywithin the peptide therapeutics contract API manufacturing market has beenanalyzed across the following segments:

§ Scale of Operation

§ Clinical

§ Commercial

 

§ Type of PeptideSynthesis Method Used

§ Chemical

§ Non-Chemical

 

§  Typeof Peptide Chemical Synthesis Method Used

  • Liquid Phase Peptide Synthesis
  • Solid Phase Peptide Synthesis
  • Hybrid Phase Peptide Synthesis

 

§ Company Size

§ Small

§ Mid-sized

§ Large / Very Large

 

§ Key geographicalregions

§ North America

§ Europe

  • Asia Pacific

 

The Peptide Therapeutics: Contract API Manufacturing Market,2020-2030

 report features thefollowing companies, which we identified to be key players in this domain:

§  AmbioPharm

§  Auspep

§  Bachem

§  BCN Peptide

§  Chinese Peptide

§  CordenPharma

§  CPC Scientific

§  Creative Peptides

§  CSBio

§  Hybio Pharmaceutical

§  PEPTIDE INSTITUTE

§  PolyPeptide Group

§  Senn Chemicals

§  Sinopharm Group

 

Table of Contents

 

1. PREFACE

 

2. EXECUTIVE SUMMARY

 

3. INTRODUCTION

 

4. REGULATORY LANDSCAPE

 

5. COMPETITIVE LANDSCAPE

 

6. COMPANY PROFILES

 

7. RECENT DEVELOPMENTS

 

8. CLINICAL TRIAL ANALYSIS

 

9. REGIONAL CAPABILITY ANALYSIS           

 

10. DEMAND ANALYSIS

 

11. CAPACITY ANALYSIS                                           

 

12. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

 

13. MARKET SIZING AND OPPORTUNITY ANALYSIS

 

14. IMPACT OF THECOVID-19 PANDEMIC ON THE PEPTIDE API CONTRACT MANUFACTURING MARKET

 

15. SWOT ANALYSIS

 

16. CONCLUSION

 

17. SURVEY TRANSCRIPT(S)

 

18. APPENDIX 1: TABULATED DATA

 

19.APPENDIX 2: LIST OF COMPANIES ANDORGANISTIONS

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/peptide-therapeutics-manufacturing/305.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com